clioquinol


Also found in: Dictionary, Thesaurus, Wikipedia.

clioquinol

Vioform, an antibacterial and antifungal drug commonly formulated in combination with a steroid drug for external use. Brand names are Betnovate C, Locorten-Vioform, Quinaband, Synalar C and Vioform-Hydrocortisone

clioquinol (klē´ōkwin´ol),

n brand name: Vioform;
drug class: topical antifungal;
action: topically to treat angular cheilitis.

clioquinol

see iodochlorhydroxyquin.
References in periodicals archive ?
Because clock-1 affects longevity in invertebrates and mice, and because we're talking about three age-dependent neurodegenerative diseases, we hypothesize that clioquinol affects them by slowing down the rate of aging," Hekimi added.
Hekimi said that the exact mechanism of how clioquinol inhibits CLK-1 is till under investigation.
One possibility is that metals are involved as clioquinol is a metal chelator," he said.
Vaccines to prevent AD have fallen short because they target amyloid beta indiscriminately, whereas clioquinol goes after the toxic, aggregated form of the protein, Dr.
In a pilot study of 36 patients, clioquinol effectively slowed cognitive loss in patients who scored greater than 25 on the AD assessment scale cognitive instrument.
One-third of young mice treated with clioquinol didn't develop detectable amyloid deposits; the others had far fewer than untreated mice did.
In collaboration with Australian scientists, the Boston researchers have begun testing clioquinol on people with mild-to-moderate Alzheimer's.
Clioquinol, which was developed 100 years ago, is able to absorb the zinc and copper atoms that concentrate in the brains of Alzheimer's sufferers such as former US President Ronald Reagan before dementia sets in.
The UCL study was prompted by research at Melbourne University in Australia and Harvard University in the States, which found that clioquinol could prevent zinc from building up on the surface of the brain.
1 /PRNewswire-FirstCall/ -- Prana Biotechnology Limited , today announced that Aging Cell, a journal addressing fundamental issues in the biology of aging, has published a new paper in its February edition entitled, "Radioiodinated Clioquinol as a Biomarker for beta-amyloid: Zn2+ complexes in Alzheimer's disease.
The paper reveals that Prana's MPACs, "Metal Protein Attenuating Compounds," as demonstrated by clioquinol (CQ), can enter the brain and seek out the relevant AD therapeutic target -- the metal-bound beta-amyloid (beta- amyloid), as Prana scientists have long hypothesized.
We have previously reported in the Journal of Clinical Investigation that the MPAC clioquinol inhibits amyloid deposition and oxidation damage in the brains of transgenic mice.